Title: CLINICAL AND DIAGNOSTIC PARALLELS OF POSTACNE MANIFESTATIONS
Author: Кондакова
Last saved by: Nancy

PREVENTION OF FUNGAL INFECTION OF THE FEET
About the author: | Ya.F. Kutasevich, I.O. Oliinyk, K.G. Suprun
Heading | clinical observations
Type of article | Scientific Article

Annotation

The objective of the work: to study the antifungal activity in vitro and to determine the 
effectiveness of using the spray containing 0.2% climbazole for the prevention of 
fungal infections of the feet.
Materials and methods.47 patients were under observation who received treatment
at the clinic of the State Establishment«Institute of Dermatology and Venereology of 
NAMS of Ukraine» for mycosis of the feet and were discharged in a state of recovery, 
confirmed by mycological negativity. When discharged, patients with a preventive 
purpose were recommended to apply a spray containing0.2% climbazole(Mycosan 
spray) to dry and clean skin twice a day for30 days with a five-day break for two 
months. Control of microscopic examination for fungi was carried out once every
2 weeks for two months. To study the protective antifungal activity of the spray in 
vitro studies were carried out with cultures of yeast-like fungi(Candida spp., strain 
No. 491) and dermatophytes (Trichophyton rubrum, strain No. 181).
Results. The article reveals the relevance of the topic, describes the probable causes 
of relapses and reinfections of a fungal infection of the feet, indicates ways to prevent
 these causes. The emphasis is placed on the fact that the main goal of therapeutic 
and prophylactic measures for fungal infection is the early detection and adequate 
treatment of patients with mycoses and onychomycosis, as well as the development 
of fundamentally new means of prevention, one of which is the spray containing
0.2% of climbazole, relatedto group of azoles which has a fungistatic effect, has a 
low level of resistance, provides protection and care for the skin of the feet.
Conclusions. Studies have shown that Mycosan spray inhibits the growth of 
pathogenic dermatophytes and yeast-like fungi in vitro. During the observation of
47 patients in the stage of clinical and mycological recovery for two months, infection 
of the fungal infection of the feet was not observed in a single patient. The spray 
containing 0.2% of climbazole can be used as an individual prevention of infection 
and reinfection, as well as an effective addition to the complex therapy of patients 
with mycoses and onychomycosis of the feet.

Tags

mycosis of the feet, onychomycosis of the feet, prevention, Mycosan spray, 
climbazole.

Bibliography

1. Bezvershenko KI. Ratsionalna terapiia riznykh klinichnykh form onikhomikoziv 
[Rational the rapy of various clinical forms of onychomycosis]. Ukrainskyi zhurnal 
dermatolohii, venerolohii ta kosmetolohii. 2018;2:95–102. [Ukr.]
2. Burova SA. Osobennosti lecheniya gribkovyh infekcij kozhi i ee pridatkov v 
gruppah riska [Features of the treatment of fungal infections of the skin and its 
appendages in risk groups]. Klinicheskaya dermatologiya i venerologiya. 2014;1:
47–51. [Rus.]
3. Lytynska TO. Onikhomikoz: suchasni mozhlyvosti topichnoi terapii 
[Onychomycosis: modern possibilities of topical therapy]. Ukr. zhurn. 
dermatolohii, venerolohii, kosmetolohii. 2019;2:88–92. [Ukr.]
4. Zaslavskij DV, CHuprov IN, Sydikov AA, et al. Onihomikoz: osobennosti 
naruzhnoj terapii [Onychomycosis: features of external therapy]. Vestn. 
dermatologii i venerologii. 2016;5:90–95. [Rus.]
5. Sergeev AYu, Mokina EV, Savchenko NV, et al. Recidivy, reinfekcii i 
effektivnost’ lecheniya onihomikozov v 2013 g. [Relapses, reinfections and the 
effectiveness of treatment of onychomycosis in 2013]. Immunopatologiya, 
allergologiya, infektologiya. 2013;3:90–99. [Rus.]
6. Savos’kina  VA.  Onihomikoz: epidemiologiya,  etiopatogenez, diagnostika,
lechenie [Onychomycosis: epidemiology, etiopathogenesis, diagnosis, treatment]. 
Dermatolohiia ta venerolohiia. 2018;2(80):76–82. [Rus.]
7. Svyatenko TV, Pyshnyak FS. Onihomikozy: rasprostranennost’, osobennosti 
techeniya i vozmozhnosti terapii na sovremennom etape v Ukraine 
[Onychomycosis: prevalence, features of the course and possibilities of therapy 
at the present stage in Ukraine]. Ukrainskyi zhurnal dermatolohii, venerolohii, 
kosmetolohii. 2018;3(70):127–132. [Rus.]
8. Sergeev VYu, Burceva GN, Baranova MO. Mestnaya terapiya onihomikozov – 
  ot preventivnogo lecheniya k profilaktike reinfekcii [Local therapy of 
onychomycosis –  from preventive treatment to prevention of reinfection]. 
Immunopatologiya, allergologiya, infektologiya. 2017;4:65–72. [Rus].
9. Stepanenko VI, Chobotar AI, Bondar SO. Dermatolohiia i venerolohiia: 
pidruchnyk dlia med. VNZ I–III r.a. [Dermatology and venereology: a textbook 
for med. universities of I–III l.a.]. Kyiv: Medytsyna; 2015. 336 p. [Ukr.]
10. Fajzullina EV. Sovremennye tendencii epidemiologii onihomikoza [Current
 trends in the epidemiology of onychomycosis]. Problemy med. mikologii. 2014;
1:18–22. [Rus.]
11. Ameen M, Lear JT, Madan V et al. British Association of Dermatologists’ 
guidelines for the management of onychomycosis 2014. Br.J. Dermatol. 2014;
171(5):937–958.
12. Gupta AK, Simpson FC. Investigational drugs for onychomycosis. Expert 
Opin. Investig. Drugs. 2014;23(1):97–106.
13. Suprun K, Kutasevych Yа, Oliinyk I, Bilozorov O, Mashtakova I, Stuliy O. 
Peculiarities of treatment of patients with onychomycosis with contraindications 
to systemic antimycotics. Wiadomości Lekarskie. 2021;LXXIV(9, 1):2070–2075.
14. Shemer A, Scher R, Farhi R et al. Why there is a wide difference in the
 clinical and mycological results in different onychomycosis clinical studies. J 
Eur Acad Dermatol Venereol. 2013;27(3):e434-e435

Publication of the article

«DERMATOLOGY AND VENEREOLOGY» №3(93), 2021 year, 12-15 pages,
 index UDK 616.596–002.828:616.521

DOI | 10.33743/2308-1066-2021-3-12-15